BPC-157 vs Exosomes
Written by Aaron CuhaReviewed Sep 2026
The short answer
Two things sold in the same clinics with the same promise. Exosomes have one trial in 110 people with diabetic foot ulcers that showed faster healing. The field also had to publish a standards document because it could not describe what it was studying the same way twice. So almost nothing sold in a clinic looks like the studied product.
- BPC-157 people
- 31
- BPC-157 nulls
- 1
- Exosomes people
- 110
- Exosomes nulls
- 0
Dose
No human dose established
No published study has given BPC-157 as a shot under the skin or as a pill, the ways most buyers take it. Amounts that circulate in forums are not a human dose. Amounts that were given in studies sit in Human evidence on this page.
Commonly reported amounts, in mcg. BPC-157 has no approved label and no completed human dosing trial.
Amounts commonly reported by people buying BPC-157, recorded for this archive's reconstitution calculator, are 250, 500 and 750 mcg. They are self-reports rather than trial doses, and this archive does not recommend any of them. No human dose has been established for BPC-157.
| Reported amount | Where the number comes from |
|---|---|
| 250 mcg | Commonly reported, no published human dosing trial |
| 500 mcg | Commonly reported, no published human dosing trial |
| 750 mcg | Commonly reported, no published human dosing trial |
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 110 people given it
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
BPC-157Body Protection Compound 157
A lab-made piece of a stomach protein. It has lots of animal studies on tendon, muscle and gut healing. In people there is very little: two enema studies in Croatia, three small clinic reports with nobody to compare against, and one injury study with a dummy group that is still signing people up.
Column B
ExosomesExosomes and small extracellular vesicles
In 110 people with diabetes foot sores, sores treated with exosomes healed in about 6 weeks, against about 20 weeks without them. What clinics sell is almost never that product. The field even had to write a rulebook, because scientists could not agree on how to describe what they were studying.
Side by side, on the facts we can check
| What we compare | BPC-157 | Exosomes |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| FDA status | Not FDA-approved. In April 2026 the FDA took it off Category 2, its list of pharmacy ingredients with safety worries. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one member abstaining, in favor of letting pharmacies make it. The FDA's own reviewers had advised against that. The FDA has not acted yet | No exosome product is approved by the FDA for any use. The FDA has said publicly that there are no approved exosome products, and it has acted against clinics selling them. So anything sold in a clinic is unapproved, whatever it is called. |
| Half-life | Under 30 minutes in plasma in a two-person pilot; the animal literature describes effects lasting hours to days. | Not meaningfully described. Systemically administered vesicles are cleared from circulation within minutes to hours, mostly by liver and spleen, which is one reason the strongest human evidence involves local application rather than infusion. |
| Molecular weight | 1,419.5 Da | Not applicable. These are vesicles rather than molecules, generally 30 to 150 nanometres in diameter. |
| How it works | In animals, BPC-157 helps grow new blood vessels. It works with nitric oxide, a gas the body uses to widen blood vessels. In tendon cells from animals, it raises growth hormone receptors and growth signals. Nobody has found the exact switch it acts on. The FDA's 2026 review gave that as one reason it could not judge whether it should work. In people, very little is known. After an enema, it could not be found in the blood. A two-person test suggests it leaves the blood in under 30 minutes. Animal studies describe effects that last hours to days. | Exosomes are very small bubbles, about 30 to 150 nanometres across. Cells build them inside and then push them out. Each one carries proteins, fats and genetic messages to other cells, and those messages can change what the other cell does. For treatment, the cargo is the real drug, not the bubble. Any effect on wounds, swelling or repair comes from what the bubble carries. That cargo depends on which cells made it and how they were grown. Two products with the same size and count can carry totally different cargo. Nothing on the label tells you which one you have. |
| Studies in people | 7 | 1 |
| Evidence | Limited: 3 completed trials, 31 people given it | Moderate: 1 completed trial, 110 people given it |
| Legal status, US | Not approved; research use only | Investigational, not approved |
Frequently asked questions
What is the difference between BPC-157 and Exosomes?
BPC-157: A lab-made piece of a stomach protein. It has lots of animal studies on tendon, muscle and gut healing. In people there is very little: two enema studies in Croatia, three small clinic reports with nobody to compare against, and one injury study with a dummy group that is still signing people up. Exosomes: In 110 people with diabetes foot sores, sores treated with exosomes healed in about 6 weeks, against about 20 weeks without them. What clinics sell is almost never that product. The field even had to write a rulebook, because scientists could not agree on how to describe what they were studying.
Which has stronger research evidence, BPC-157 or Exosomes?
Each compound gets a band worked out from facts we counted, with the math shown. BPC-157 is Limited (3 completed trials, 31 people given it). Exosomes is Moderate (1 completed trial, 110 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are BPC-157 and Exosomes FDA-approved?
BPC-157: Not FDA-approved. In April 2026 the FDA took it off Category 2, its list of pharmacy ingredients with safety worries. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one member abstaining, in favor of letting pharmacies make it. The FDA's own reviewers had advised against that. The FDA has not acted yet. Exosomes: No exosome product is approved by the FDA for any use. The FDA has said publicly that there are no approved exosome products, and it has acted against clinics selling them. So anything sold in a clinic is unapproved, whatever it is called..
Related posts
Blog articles that cover BPC-157 or Exosomes, newest first.
- Healing & Recovery / Sep 27, 2026 / 9 minPeptides for Joint Pain: BPC-157, TB-500, Lorecivivint, Pentosan and Collagen Peptides, Evidence Tiered
- Healing & Recovery / Sep 27, 2026 / 8 minPeptides for Gut Health: BPC-157, KPV and Larazotide Ranked by Human Evidence
- Safety / Sep 27, 2026 / 9 minPeptide Side Effects by Class: What Is Documented, What Is Anecdotal
- Safety / Sep 27, 2026 / 8 minHow to Read a Peptide Certificate of Analysis: HPLC Purity, Mass Spec Identity, Endotoxin, and Janoshik Verification
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.